Published on 24/12/2025

Generating High-Impact Real-World Evidence from Phase 4 Clinical Trials

Introduction

Real-World Evidence (RWE) has emerged as a powerful supplement to traditional clinical trial data, especially in Phase 4 trials. Generated from everyday patient experiences and routine care, RWE provides actionable insights that inform healthcare decisions, payer coverage, guideline development, and regulatory actions.

Sources of RWE in Phase 4

• Electronic Health Records (EHRs)
• Insurance Claims Data
• Patient Registries
• Mobile Health Applications
• Social Media and Patient Forums

How RWE Enhances Phase 4 Objectives

• Safety Monitoring: Identify rare adverse events and risk patterns
• Effectiveness in Real Use: Capture how a drug performs outside of trial conditions
• Cost-Effectiveness: Evaluate economic outcomes like hospitalizations avoided
• Disease Burden Tracking: Understand treatment gaps and comorbidity impact

Examples of RWE-Driven Decisions

Data from RWE platforms led to label changes for antihypertensives in Black patients based on differential response. Another example is the approval of Palbociclib for male breast cancer based solely on RWE from Flatiron Health’s database.

Designing RWE Studies in Phase 4

• Define Objective: Safety, effectiveness, adherence, economics
• Select Data Source: Choose validated datasets with appropriate patient coverage
• Apply Statistical Adjustments: Confounding, bias correction, missing data imputation
• Pre-register: On EU PAS Register or ClinicalTrials.gov

Regulatory Acceptance of RWE

• FDA: Accepts RWE under RWE Framework and 21st Century Cures Act
• EMA: Initiatives